Skip to main content
SpringerLink
Log in

Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors

  • Practice/Case Reports
  • Published:
Pharmacy World and Science Aims and scope Submit manuscript

Abstract

Decision analysis is applied to the group of angiotensin-converting enzyme inhibitors, in order to select those which should be included in the hospital formulary and to establish a research method which allows the reproduction of the process with new, related drugs. Captopril, enalapril and lisinopril were the alternatives considered. Evaluation criteria were efficacy, clinical experience, safety, dosage interval, hepatic bioactivation, interactions, dosage forms and cost. A relative weight was assigned through a survey among the hospital's staff. Each alternative was evaluated in relation to all criteria. Sensitivity analysis was applied to validate the method. Enalapril obtained the highest score, followed by lisinopril and captopril. The sensitivity analysis confirms this result. Enalapril is selected for the hospital formulary due to its higher score, although the differences between the three are very small.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yang HY, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970;214:374–6.

    PubMed  Google Scholar 

  2. Lant AF, McNabb RW, Noormohamed FH. Kinetic and metabolic aspects of enalapril action. J Hypertens 1984;2(Suppl 2):37–42.

    PubMed  Google Scholar 

  3. Wu MT, Douglas AW, Ondeika DL, Payme LG, Ikeler TJ, Joshua H. Synthesis of N2-(1-carboxy-3-phenylpropyl)-L-lysyl-l-proline (lisinopril). J Pharm Sci 1985;74:352–4.

    PubMed  Google Scholar 

  4. Weinstein MC, Fineberg HV, editors. Clinical decision analysis. Philadelphia: W.B. Saunders, 1980.

    Google Scholar 

  5. Einarson TR, McGhan WF, Bootman JL. Decision analysis applied to pharmacy practice. Am J Hosp Pharm 1985;42:364–71.

    PubMed  Google Scholar 

  6. Witte KW, Eck TA, Vogel DP. Decision analysis applied to the purchase of frozen premixed intravenous admixtures. Am J Hosp Pharm 1985;42:835–9.

    PubMed  Google Scholar 

  7. Schumacher GE, Barr JT. Applying decision analysis in therapeutic drug monitoring: using decision trees to interpret serum theophylline concentrations. Clin Pharm 1986;5:325–33.

    PubMed  Google Scholar 

  8. Corder MP, Ellwein LB. Comparison of treatments for symptomatic Hodkgin's lymphoma employing decision analysis. Am J Clin Oncol 1984;7(1):33–8.

    PubMed  Google Scholar 

  9. Cano SB, Fujita NK. Formulary evaluation of third-generation cephalosporins using decision analysis. Am J Hosp Pharm 1988,45:566–9.

    PubMed  Google Scholar 

  10. Calvo MV, Fruns I, Dominguez-Gil A. Decision analysis applied to selection of histamine H2-receptor antagonists for the formulary. Am J Hosp Pharm 1990;47:2002–6.

    PubMed  Google Scholar 

  11. Kresel JJ, Hutchings C, Mackay DN, Delagrauge M, Harckel MD, Frearsou S,et al. Application of decision analysis to drug selection for formulary addition. Hosp Formul 1987;22:658–76.

    PubMed  Google Scholar 

  12. Dukes MNG, editor. Meyler's side effects of drugs. 11th ed. Amsterdam: Excerpta Medica, 1988.

    Google Scholar 

  13. McEvoy GK, editor. AHFS drug information 90. Bethesda: American Society of Hospital Pharmacists, 1990.

    Google Scholar 

  14. United States Pharmacopeia. Drug Information for the health care professional. Volumes IA + IB. 9th ed. Rockville: The United States Pharmacopeial Convention, 1989.

    Google Scholar 

  15. Raia JJ, Barone JA, Byerly WG, Lacy CR. Angiotensin-converting enzyme inhibitors: a comparative review. Drug Intell Clin Pharm 1990;24:506–25.

    Google Scholar 

  16. Zanella MT, Salgado BJ, Kohlman Jr O, Ribeiro AB. Angiotensin-converting enzyme inhibition. Therapeutic option for diabetic hypertensive patients. Drugs 1990;39 (Suppl 2):33–9.

    Google Scholar 

  17. Fyhrquist F. Clinical pharmacology of the angiotensin converting enzyme inhibitors. Drugs 1986;32:33–9.

    Google Scholar 

  18. Laher MS. Lisinopril in elderly patients with hypertension. Long term effects on renal and metabolic function. Drugs 1990;39(Suppl 2):55–63.

    PubMed  Google Scholar 

  19. Giles TD. Clinical experience with lisinopril in congestive heart failure. Focus on the older patient. Drugs 1990;39(Suppl 2):17–22.

    PubMed  Google Scholar 

  20. Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429–35.

    Google Scholar 

  21. Swedberg K, Kjekshus J. Effect of enalapril on mortality in congestive heart failure. Follow-up survival data from the Consensus Trial. Drugs 1990;39(Suppl 4):49–52.

    Google Scholar 

  22. Eriksson SV, Offstad J, Kjekshus J. M-mode echocardiography in patients with severe congestive heart failure. A subgroup analysis in the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Drugs 1990;39(Suppl 4):43–8.

    Google Scholar 

  23. Powers ER, Chiaramida A, Demaria AN, Giles TD, Hackshaw B, Hart W,et al. A double-blind comparison of lisinopril with captopril in patients with symptomatic congestive heart failure. J Cardiovasc Pharmacol 1987;9(Suppl 3):S82–8.

    PubMed  Google Scholar 

  24. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Mouma H, Ishizaki M,et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985;313:1617–20.

    PubMed  Google Scholar 

  25. Reams GP, Bauer JH. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med 1986;146:2145–8.

    PubMed  Google Scholar 

  26. Heeg JE, De Jong PE, Van der Hem GK, De Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989;36:272–9.

    PubMed  Google Scholar 

  27. López-Ovejero JA, Sall SD, D'Angelo WA, Cheigh JS, Stenzel KH, Laragh JH. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting enzyme blockade. N Engl J Med 1979;300:1417–9.

    PubMed  Google Scholar 

  28. Ferder LF, Inserra F, Daccordi H, Romano L, Fernández A, Tessler J. Effects of enalapril on renal parameters in patients with primary glomerulopathies associated with chronic renal failure. Drugs 1990;39(Suppl 2):40–6.

    PubMed  Google Scholar 

  29. Thurm RH, Alexander JC. Captopril in the treatment of scleroderma renal crisis. Arch Intern Med 1984;144:733–5.

    PubMed  Google Scholar 

  30. Smith CD, Smith RD, Korn JH. Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor MK 421 (enalapril) in captopril-intolerant patients. Arthritis Rheum 1984;27:826–8.

    PubMed  Google Scholar 

  31. Miyazaki S, Miura K, Kasai Y, Abe K, Yoshinaga K. Relief from digital vasospasm by treatment with captopril and its complete inhibition by serine proteinase inhibitors in Raynaud's phenomenon. BMJ 1982;284:310–1.

    PubMed  Google Scholar 

  32. Mimran A, Targhetta R. Captopril treatment of idiopathic edema. N Engl J Med 1979;301:l289–90.

    Google Scholar 

  33. Tschollar W, Belz CG. Sublingual captopril in hypertensive crisis. Lancet 1985;2:34–5.

    Google Scholar 

  34. Rocci ML, Shaw EW, Vlasses PH, Ferguson RK. Bioactivation of the angiotensin converting enzyme inhibitor enalapril in cirrhosis [abstract]. Clin Res 1986;34:406A.

    Google Scholar 

  35. Salvetti A, Pedrinelli R, Magagna A, Abdel-Haq B, Graziadei L, Taddei S,et al. Influence of food on acute and chronic effects of captopril in essential hypertensive patients. J Cardiovasc Pharmacol 1985;7(Suppl 2):25–9.

    Google Scholar 

  36. Swanson BN, Vlasses PH, Ferguson RK, Bergquist PA, Till AE, Irvin JD,et al. Influence of food on the bioavailability of enalapril. J Pharm Sci 1984;73:1655–7.

    PubMed  Google Scholar 

  37. Mojaverian P, Rocci ML, Vlasses PH, Hoholick C, Clementi RA, Ferguson RK. Effect on food on the bioavailability of lisinopril, a non-sulfhydryl angiotensin-converting enzyme inhibitor. J Pharm Sci 1986;75:395–7.

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. María José Piña Vera

    Present address: FREMAP Hospital de Rehabilitación, Sevilla, Spain

Authors and Affiliations

  1. Servicio de Farmacia, Hospital Vírgen del Rocío, Servicio Andaluz de Salud, c/ Azucena 36, 41010, Sevilla, Spain

    Bernardo Santos Ramos, María José Piña Vera, Encarnación Carvajal Gragera & Manuela Atienza Fernández

Authors
  1. Bernardo Santos Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María José Piña Vera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Encarnación Carvajal Gragera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manuela Atienza Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramos, B.S., Vera, M.J.P., Gragera, E.C. et al. Decision analysis applied to the selection of angiotensin-converting enzyme inhibitors. Pharm World Sci 15, 219–224 (1993). https://doi.org/10.1007/BF01880630

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01880630

Keywords

Search

Navigation